# Genrix Bio

Source: https://onco.cc/companies/genrix-bio/  
OnCo record `genrix-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Genrix Bio is a Shanghai antibody company, listed on the Shanghai STAR market, whose oncology lead GR1803 is a BCMA and CD3 bispecific T-cell engager for multiple myeloma.

## Summary

Genrix (Shanghai) Biopharmaceutical, a subsidiary of Zhifei Biological Products, develops monoclonal and bispecific antibodies. Its first approved product is the IL-17A antibody xeligekimab for psoriasis; its pipeline spans autoimmune, infectious and cancer indications. GR1803, a bispecific antibody binding BCMA on myeloma cells and CD3 on T cells, is in a phase 1/2 trial in relapsed or refractory multiple myeloma.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Genrix (Shanghai) Biopharmaceutical; 智翔金泰; SSE:688443
- Tags: drug-maker
- HQ: Shanghai
- Type: biotech
- Ticker: SSE:688443

## Connected records

- drugs: [GR1803](https://onco.cc/drugs/gr1803/)

---
JSON: https://onco.cc/api/v1/entities/genrix-bio.json